Orion and Peptilogics are pursuing AI-driven drug discovery to explore new functional chemical ...

GPCR News
Jun 30, 2022
1 min read

Updated: Aug 18, 2022

July 2022

"Orion Biotechnology and Peptilogics are pursuing AI-driven drug discovery to explore new functional chemical space and precision-engineer therapeutics with enhanced potency and tailored signaling against an undrugged GPCR target.

#ai #drugdiscovery #gpcr"

Recent Posts

See All

Emerging approaches for decoding neuropeptide transmission

November 2022 "Neuropeptides produce robust effects on behavior across species, and recent research has benefited from advances in...

Location bias contributes to functionally selective responses of biased CXCR3 agonists

November 2022 "Some G protein-coupled receptor (GPCR) ligands act as "biased agonists" that preferentially activate specific signaling...

Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...

November 2022 Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell cycle and metastasis...

GPCR News Powered by our Strategic Partners

Orion and Peptilogics are pursuing AI-driven drug discovery to explore new functional chemical ...

Recent Posts

Comments

Explore the Ecosystem

Foundry

University

Strategic Partners